Found: 305
Select item for more details and to access through your institution.
Lower intensity therapy with cladribine/low dose cytarabine/venetoclax in older patients with acute myeloid leukemia compares favorably with intensive chemotherapy among patients undergoing allogeneic stem cell transplantation.
- Published in:
- Cancer (0008543X), 2024, v. 130, n. 19, p. 3333, doi. 10.1002/cncr.35388
- By:
- Publication type:
- Article
A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia.
- Published in:
- Investigational New Drugs, 2008, v. 26, n. 4, p. 331, doi. 10.1007/s10637-008-9129-0
- By:
- Publication type:
- Article
Modeling interactions between leukemia-specific chromosomal changes, somatic mutations, and gene expression patterns during progression of core-binding factor leukemias.
- Published in:
- Genes, Chromosomes & Cancer, 2010, v. 49, n. 2, p. 182, doi. 10.1002/gcc.20732
- By:
- Publication type:
- Article
Exploring the landscape of somatic ASXL2 mutations in myeloid neoplasms: Frequency and clinical implications.
- Published in:
- American Journal of Hematology, 2024, v. 99, n. 7, p. 1434, doi. 10.1002/ajh.27333
- By:
- Publication type:
- Article
Targetable genetic abnormalities in patients with acute myeloblastic leukemia across age groups.
- Published in:
- American Journal of Hematology, 2024, v. 99, n. 4, p. 792, doi. 10.1002/ajh.27236
- By:
- Publication type:
- Article
Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 11, p. 1780, doi. 10.1002/ajh.27070
- By:
- Publication type:
- Article
Phase II study of cladribine, idarubicin, and ara‐C (CLIA) with or without sorafenib as initial therapy for patients with acute myeloid leukemia.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 11, p. 1711, doi. 10.1002/ajh.27054
- By:
- Publication type:
- Article
Performance of IPSS‐M in patients with myelodysplastic syndrome after hypomethylating agent failure.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 10, p. E281, doi. 10.1002/ajh.27043
- By:
- Publication type:
- Article
Outcomes of adult patients with relapsed/refractory CRLF2 rearranged B‐cell acute lymphoblastic leukemia.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 6, p. E142, doi. 10.1002/ajh.26907
- By:
- Publication type:
- Article
Common kinase mutations do not impact optimal molecular responses in core binding factor acute myeloid leukemia treated with fludarabine, cytarabine, and G‐CSF based regimens.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 3, p. E53, doi. 10.1002/ajh.26811
- By:
- Publication type:
- Article
Implications of RAS mutational status in subsets of patients with newly diagnosed acute myeloid leukemia across therapy subtypes.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 12, p. 1599, doi. 10.1002/ajh.26731
- By:
- Publication type:
- Article
Differential prognostic impact of RUNX1 mutations according to frontline therapy in patients with acute myeloid leukemia.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 12, p. 1560, doi. 10.1002/ajh.26724
- By:
- Publication type:
- Article
Retrospective comparison of survival and responses to Fludarabine, Cytarabine, GCSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or Idarubicin (IDA) in patients with newly diagnosed core binding factor (CBF) acute myelogenous leukemia: MD Anderson experience in 174 patients
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 11, p. 1427, doi. 10.1002/ajh.26700
- By:
- Publication type:
- Article
Contemporary outcomes in IDH‐mutated acute myeloid leukemia: The impact of co‐occurring NPM1 mutations and venetoclax‐based treatment.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 11, p. 1443, doi. 10.1002/ajh.26694
- By:
- Publication type:
- Article
Low‐dose dasatinib 50 mg/day versus standard‐dose dasatinib 100 mg/day as frontline therapy in chronic myeloid leukemia in chronic phase: A propensity score analysis.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 11, p. 1413, doi. 10.1002/ajh.26689
- By:
- Publication type:
- Article
Venetoclax combined with FLAG‐IDA induction and consolidation in newly diagnosed acute myeloid leukemia.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 8, p. 1035, doi. 10.1002/ajh.26601
- By:
- Publication type:
- Article
Urgent cytoreduction for newly diagnosed acute myeloid leukemia patients allows acquisition of pretreatment genomic data and enrollment on investigational clinical trials.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 7, p. 885, doi. 10.1002/ajh.26572
- By:
- Publication type:
- Article
Treatment‐free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 7, p. 856, doi. 10.1002/ajh.26550
- By:
- Publication type:
- Article
Prediction of survival with intensive chemotherapy in acute myeloid leukemia.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 7, p. 865, doi. 10.1002/ajh.26557
- By:
- Publication type:
- Article
Activity of decitabine as maintenance therapy in core binding factor acute myeloid leukemia.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 5, p. 574, doi. 10.1002/ajh.26496
- By:
- Publication type:
- Article
Improved outcomes among newly diagnosed patients with FMS‐like tyrosine kinase 3 internal tandem duplication mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the European LeukemiaNet adverse risk classification.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 3, p. 329, doi. 10.1002/ajh.26451
- By:
- Publication type:
- Article
Prediction of early (4‐week) mortality in acute myeloid leukemia with intensive chemotherapy.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 1, p. 68, doi. 10.1002/ajh.26395
- By:
- Publication type:
- Article
Long‐term results of low‐intensity chemotherapy with clofarabine or cladribine combined with low‐dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 8, p. 914, doi. 10.1002/ajh.26206
- By:
- Publication type:
- Article
FLT3 inhibitor based induction and allogeneic stem cell transplant in complete remission 1 improve outcomes in patients with newly diagnosed Acute Myeloid Leukemia with very low FLT3 allelic burden.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 8, p. E275, doi. 10.1002/ajh.26202
- By:
- Publication type:
- Article
Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment‐related mortality.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 3, p. 282, doi. 10.1002/ajh.26061
- By:
- Publication type:
- Article
The LEukemia Artificial Intelligence Program (LEAP) in chronic myeloid leukemia in chronic phase: A model to improve patient outcomes.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 2, p. 241, doi. 10.1002/ajh.26047
- By:
- Publication type:
- Article
Clinical outcomes and influence of mutation clonal dominance in oligomonocytic and classical chronic myelomonocytic leukemia.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 2, p. E50, doi. 10.1002/ajh.26044
- By:
- Publication type:
- Article
Natural history of newly diagnosed myelodysplastic syndrome with isolated inv(3)/t(3;3).
- Published in:
- American Journal of Hematology, 2020, v. 95, n. 12, p. E326, doi. 10.1002/ajh.25991
- By:
- Publication type:
- Article
Clonal evolution and treatment outcomes in hematopoietic neoplasms arising in patients with germline RUNX1 mutations.
- Published in:
- American Journal of Hematology, 2020, v. 95, n. 11, p. E313, doi. 10.1002/ajh.25965
- By:
- Publication type:
- Article
Phase 1 study of combinatorial sorafenib, G‐CSF, and plerixafor treatment in relapsed/refractory, FLT3‐ITD‐mutated acute myelogenous leukemia patients.
- Published in:
- American Journal of Hematology, 2020, v. 95, n. 11, p. 1296, doi. 10.1002/ajh.25943
- By:
- Publication type:
- Article
Phase I/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemia.
- Published in:
- American Journal of Hematology, 2020, v. 95, n. 11, p. 1288, doi. 10.1002/ajh.25939
- By:
- Publication type:
- Article
The clinical impact of time to response in de novo accelerated‐phase chronic myeloid leukemia.
- Published in:
- American Journal of Hematology, 2020, v. 95, n. 10, p. 1127, doi. 10.1002/ajh.25907
- By:
- Publication type:
- Article
Impact of CD33 and ABCB1 single nucleotide polymorphisms in patients with acute myeloid leukemia and advanced myeloid malignancies treated with decitabine plus gemtuzumab ozogamicin.
- Published in:
- American Journal of Hematology, 2020, v. 95, n. 9, p. E225, doi. 10.1002/ajh.25854
- By:
- Publication type:
- Article
Comparison of therapy‐related and de novo core binding factor acute myeloid leukemia: A bone marrow pathology group study.
- Published in:
- American Journal of Hematology, 2020, v. 95, n. 7, p. 799, doi. 10.1002/ajh.25814
- By:
- Publication type:
- Article
Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy.
- Published in:
- American Journal of Hematology, 2020, v. 95, n. 6, p. 612, doi. 10.1002/ajh.25769
- By:
- Publication type:
- Article
Acute myeloid leukemia with a novel CPSF6‐RARG variant is sensitive to homoharringtonine and cytarabine chemotherapy.
- Published in:
- American Journal of Hematology, 2020, v. 95, n. 2, p. E48, doi. 10.1002/ajh.25689
- By:
- Publication type:
- Article
Prognostic significance of baseline FLT3-ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib.
- Published in:
- American Journal of Hematology, 2019, v. 94, n. 9, p. 984, doi. 10.1002/ajh.25553
- By:
- Publication type:
- Article
Intensive chemotherapy is more effective than hypomethylating agents for the treatment of younger patients with myelodysplastic syndrome and elevated bone marrow blasts.
- Published in:
- American Journal of Hematology, 2019, v. 94, n. 7, p. E188, doi. 10.1002/ajh.25490
- By:
- Publication type:
- Article
NPM1 mutant variant allele frequency correlates with leukemia burden but does not provide prognostic information in NPM1‐mutated acute myeloid leukemia.
- Published in:
- American Journal of Hematology, 2019, v. 94, n. 6, p. E158, doi. 10.1002/ajh.25454
- By:
- Publication type:
- Article
Prognostic significance of hyperdiploidy in adult acute myeloid leukemia.
- Published in:
- American Journal of Hematology, 2018, v. 93, n. 11, p. E357, doi. 10.1002/ajh.25240
- By:
- Publication type:
- Article
Prognosis of patients with intermediate risk IPSS‐R myelodysplastic syndrome indicates variable outcomes and need for models beyond IPSS‐R.
- Published in:
- American Journal of Hematology, 2018, v. 93, n. 10, p. 1245, doi. 10.1002/ajh.25234
- By:
- Publication type:
- Article
Sorafenib Combined with 5‐azacytidine in Older Patients with Untreated FLT3‐ITD Mutated Acute Myeloid Leukemia.
- Published in:
- American Journal of Hematology, 2018, v. 93, n. 9, p. 1136, doi. 10.1002/ajh.25198
- By:
- Publication type:
- Article
A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms.
- Published in:
- American Journal of Hematology, 2018, v. 93, n. 2, p. 277, doi. 10.1002/ajh.24972
- By:
- Publication type:
- Article
Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors.
- Published in:
- American Journal of Hematology, 2018, v. 93, n. 1, p. 84, doi. 10.1002/ajh.24943
- By:
- Publication type:
- Article
Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma.
- Published in:
- American Journal of Hematology, 2018, v. 93, n. 1, p. 91, doi. 10.1002/ajh.24947
- By:
- Publication type:
- Article
Clinical outcomes in adult patients with aplastic anemia: A single institution experience.
- Published in:
- American Journal of Hematology, 2017, v. 92, n. 12, p. 1295, doi. 10.1002/ajh.24897
- By:
- Publication type:
- Article
Minimal residual disease eradication with epigenetic therapy in core binding factor acute myeloid leukemia.
- Published in:
- American Journal of Hematology, 2017, v. 92, n. 9, p. 845, doi. 10.1002/ajh.24782
- By:
- Publication type:
- Article
Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents.
- Published in:
- American Journal of Hematology, 2017, v. 92, n. 7, p. 599, doi. 10.1002/ajh.24735
- By:
- Publication type:
- Article
An exploratory clinical trial of bortezomib in patients with lower risk myelodysplastic syndromes.
- Published in:
- American Journal of Hematology, 2017, v. 92, n. 7, p. 674, doi. 10.1002/ajh.24746
- By:
- Publication type:
- Article
Impact of achievement of complete cytogenetic response on outcome in patients with myelodysplastic syndromes treated with hypomethylating agents.
- Published in:
- American Journal of Hematology, 2017, v. 92, n. 4, p. 351, doi. 10.1002/ajh.24650
- By:
- Publication type:
- Article